Cargando…

Update on omicron variant: What we know so far

The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhary, Gajendra, Prajapat, Manisha, Kumaravel, J, Prabha, Praisy K, Sarma, Phulen, Handa, Vrishbhanu, Kaur, Harminder, Patel, Ajay Prakash, Medhi, Bikash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012418/
https://www.ncbi.nlm.nih.gov/pubmed/35343206
http://dx.doi.org/10.4103/ijp.ijp_955_21
_version_ 1784687792144515072
author Choudhary, Gajendra
Prajapat, Manisha
Kumaravel, J
Prabha, Praisy K
Sarma, Phulen
Handa, Vrishbhanu
Kaur, Harminder
Patel, Ajay Prakash
Medhi, Bikash
author_facet Choudhary, Gajendra
Prajapat, Manisha
Kumaravel, J
Prabha, Praisy K
Sarma, Phulen
Handa, Vrishbhanu
Kaur, Harminder
Patel, Ajay Prakash
Medhi, Bikash
author_sort Choudhary, Gajendra
collection PubMed
description The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals.
format Online
Article
Text
id pubmed-9012418
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-90124182022-04-16 Update on omicron variant: What we know so far Choudhary, Gajendra Prajapat, Manisha Kumaravel, J Prabha, Praisy K Sarma, Phulen Handa, Vrishbhanu Kaur, Harminder Patel, Ajay Prakash Medhi, Bikash Indian J Pharmacol Short Communication The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals. Wolters Kluwer - Medknow 2022 2022-03-18 /pmc/articles/PMC9012418/ /pubmed/35343206 http://dx.doi.org/10.4103/ijp.ijp_955_21 Text en Copyright: © 2022 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Short Communication
Choudhary, Gajendra
Prajapat, Manisha
Kumaravel, J
Prabha, Praisy K
Sarma, Phulen
Handa, Vrishbhanu
Kaur, Harminder
Patel, Ajay Prakash
Medhi, Bikash
Update on omicron variant: What we know so far
title Update on omicron variant: What we know so far
title_full Update on omicron variant: What we know so far
title_fullStr Update on omicron variant: What we know so far
title_full_unstemmed Update on omicron variant: What we know so far
title_short Update on omicron variant: What we know so far
title_sort update on omicron variant: what we know so far
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012418/
https://www.ncbi.nlm.nih.gov/pubmed/35343206
http://dx.doi.org/10.4103/ijp.ijp_955_21
work_keys_str_mv AT choudharygajendra updateonomicronvariantwhatweknowsofar
AT prajapatmanisha updateonomicronvariantwhatweknowsofar
AT kumaravelj updateonomicronvariantwhatweknowsofar
AT prabhapraisyk updateonomicronvariantwhatweknowsofar
AT sarmaphulen updateonomicronvariantwhatweknowsofar
AT handavrishbhanu updateonomicronvariantwhatweknowsofar
AT kaurharminder updateonomicronvariantwhatweknowsofar
AT patelajayprakash updateonomicronvariantwhatweknowsofar
AT medhibikash updateonomicronvariantwhatweknowsofar